


Ranimustine

Cat. No.:	HY-13739
CAS No.:	58994-96-0
Molecular Formula:	C ₁₀ H ₁₈ ClN ₃ O ₇
Molecular Weight:	327.72
Target:	DNA Alkylator/Crosslinker
Pathway:	Cell Cycle/DNA Damage
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Ranimustine (MCNU) is a nitrosourea alkylating agent, can be used for research of chronic myelogenous leukemia and polycythemia vera ^{[1][3][4]} .
In Vivo	Ranimustine reduces spermidine and spermine in the corpus striatum, and spermine in the diencephalon, but increases putrescine in the corpus striatum and combined thalamus and hypothalamus ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Kameoka Y, et al. Safety and efficacy of high-dose ranimustine (MCNU) containing regimen followed by autologous stem cell transplantation for diffuse large B-cell lymphoma. *Int J Hematol.* 2018 Nov;108(5):510-515.
- [2]. Watanabe S, et al. Chemotherapeutic choice of ranimustine or nimustine on the basis of regional polyamine levels in rat brain. *Methods Find Exp Clin Pharmacol.* 2008 Mar;30(2):115-20.
- [3]. Kitajima K, et al. [Chemotherapy of chronic myelogenous leukemia--VP(M) regimen initiated during its chronic phase, and evaluation of MCNU in the phase of blastic crisis]. *Gan To Kagaku Ryoho.* 1989 Nov;16(11):3573-9. Japanese.
- [4]. Nagai M, et al. [Therapeutic effect of ranimustine (MCNU) on essential thrombocythemia and polycythemia vera]. *Gan To Kagaku Ryoho.* 1988 Dec;15(12):3267-70. Japanese.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA